AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 55,763.00 | Rrpk | Tdktmvkq |
AstraZeneca Posts Solid Q4 as Research and Development Continues To Make Strong Progress
AstraZeneca reported fourth-quarter results and 2023 guidance largely in line with our expectations, and we don’t expect any major changes to our fair value estimate based on the update. We continue to view Astra as undervalued, with the market not fully appreciating its industry-leading pipeline development and strong current product portfolio that helps to reinforce its wide moat.